On Nov 07, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $167 to $210.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and maintains the target price at $200.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and maintains the target price at $210.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $203 to $209.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $200 to $193.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta's recent third-quarter results surpassed expectations with significant beats in both total and Elevidys revenue. The company's maintained guidance for Elevidys is perceived to be on the cautious side.
Sales of Elevidys exhibited growth surpassing expectations in the third quarter, accompanied by positive remarks from management regarding its market introduction. Analysts believe the indicators are consistently suggesting that Elevidys has the potential to evolve into a multi-billion-dollar product, which could be further augmented by a series of gene therapy releases anticipated over the forthcoming five years.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$Sarepta Therapeutics (SRPT.US)$的評級，目標價介於167美元至210美元。
摩根士丹利分析師Michael Ulz維持買入評級，維持目標價200美元。
美銀證券分析師Tazeen Ahmad維持買入評級，維持目標價210美元。
巴克萊銀行分析師Gena Wang維持買入評級，並將目標價從203美元上調至209美元。
TD Cowen分析師Ritu Baral維持買入評級，維持目標價203美元。
貝雅分析師Brian Skorney維持買入評級，並將目標價從200美元下調至193美元。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
以下爲今日9位分析師對$Sarepta Therapeutics (SRPT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
